Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A for penile rehabilitation after nerve-sparing radical prostatectomy
ACTRN12623001007628Phase 3Not yet recruiting
- Sponsor
- A/Prof Homayoun Zargar
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in erectile dysfunction (ED) comparing Botulinum toxin type A with Placebo normal saline (2 arms). Primary endpoint: Sexual Health Inventory for Men (SHIM) score at 6 months. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on ACTRN12623001007628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001007628.